Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers
Sponsor: The Netherlands Cancer Institute
A NA clinical study on Ovarian Cancer Recurrent, this trial is ongoing. The trial is conducted by The Netherlands Cancer Institute and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Nov 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Nov 2021 — Nov 2023 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting · Phase: PHASE3 → NA
-
Feb 2021 — Nov 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Netherlands Cancer Institute
- Uppsala University
- Uppsala University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .